Oncodia secures exclusive, worldwide license to key technology


On March 15, 2019, Oncodia entered an exclusive, worldwide agreement with Temasek Life Science Laboratories, Singapore (TLL), on the commercialization of TLL’s patented PBR pattern recognition technology for DNA and RNA analyses. The technology enables fast and accurate comparisons of tumor and normal DNA to identify somatic mutations, avoiding the untestable assumptions embedded in competing solutions. The PBR technology was developed at TLL and Uppsala University by Ian Cheong and Tobias Sjöblom, co-founders of Oncodia.

More from our blog